NZ629898A - Compositions and methods for inhibition of cathepsins - Google Patents

Compositions and methods for inhibition of cathepsins

Info

Publication number
NZ629898A
NZ629898A NZ629898A NZ62989813A NZ629898A NZ 629898 A NZ629898 A NZ 629898A NZ 629898 A NZ629898 A NZ 629898A NZ 62989813 A NZ62989813 A NZ 62989813A NZ 629898 A NZ629898 A NZ 629898A
Authority
NZ
New Zealand
Prior art keywords
thiosemicarbazone
methods
benzene
cathepsins
inhibition
Prior art date
Application number
NZ629898A
Other languages
English (en)
Inventor
David J Chaplin
Devanna Kumar Kishore Gaddale
Erica Parker
Kevin G Pinney
Jiangli Song
Mary L Trawick
Original Assignee
Oxigene Inc
Univ Baylor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxigene Inc, Univ Baylor filed Critical Oxigene Inc
Publication of NZ629898A publication Critical patent/NZ629898A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C337/00Derivatives of thiocarbonic acids containing functional groups covered by groups C07C333/00 or C07C335/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C337/06Compounds containing any of the groups, e.g. thiosemicarbazides
    • C07C337/08Compounds containing any of the groups, e.g. thiosemicarbazides the other nitrogen atom being further doubly-bound to a carbon atom, e.g. thiosemicarbazones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/782Ketones containing a keto group bound to a six-membered aromatic ring polycyclic
    • C07C49/784Ketones containing a keto group bound to a six-membered aromatic ring polycyclic with all keto groups bound to a non-condensed ring
    • C07C49/786Benzophenone

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NZ629898A 2012-03-23 2013-03-05 Compositions and methods for inhibition of cathepsins NZ629898A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261615091P 2012-03-23 2012-03-23
PCT/US2013/029106 WO2013142038A2 (en) 2012-03-23 2013-03-05 Compositions and methods for inhibition of cathepsins

Publications (1)

Publication Number Publication Date
NZ629898A true NZ629898A (en) 2016-04-29

Family

ID=49223437

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ629898A NZ629898A (en) 2012-03-23 2013-03-05 Compositions and methods for inhibition of cathepsins

Country Status (7)

Country Link
US (3) US8877967B2 (enExample)
EP (1) EP2828241B1 (enExample)
JP (1) JP6231548B2 (enExample)
AU (1) AU2013235729B2 (enExample)
CA (1) CA2865504A1 (enExample)
NZ (1) NZ629898A (enExample)
WO (1) WO2013142038A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6231548B2 (ja) * 2012-03-23 2017-11-15 マテオン セラピューティクス, インコーポレイテッド カテプシンの阻害のための組成物および方法
US9884719B2 (en) 2014-12-12 2018-02-06 Symbotic, LLC Storage and retrieval system
CN119954746A (zh) 2016-07-25 2025-05-09 波音公司 环氧树脂
US11420920B2 (en) * 2016-12-21 2022-08-23 Solvay Specialty Polymers Usa, Llc Method for decreasing the concentration of a metal in a monomer composition comprising bis(benzoyl)benzene
US20180198740A1 (en) * 2017-01-06 2018-07-12 David Rademacher System and method for sharing and updating contact information
US11766467B2 (en) 2017-09-01 2023-09-26 University Of Wyoming Methods of treating wounds using cathepsin K inhibitors
US10758559B1 (en) 2017-09-01 2020-09-01 University Of Wyoming Targeting cathepsin K to facilitate wound healing
US10487057B1 (en) * 2018-07-05 2019-11-26 Landos Biopharma, Inc. NLRX1 ligands
CN110857267B (zh) * 2018-08-22 2022-12-09 昱镭光电科技股份有限公司 芳香酮化合物及其有机发光器件
US11303629B2 (en) 2019-09-26 2022-04-12 Bank Of America Corporation User authentication using tokens
US11329823B2 (en) 2019-09-26 2022-05-10 Bank Of America Corporation User authentication using tokens

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US5087240A (en) 1983-08-18 1992-02-11 Drug Delivery Systems Inc. Transdermal drug patch with conductive fibers
US4921475A (en) 1983-08-18 1990-05-01 Drug Delivery Systems Inc. Transdermal drug patch with microtubes
US4738851A (en) 1985-09-27 1988-04-19 University Of Iowa Research Foundation, Inc. Controlled release ophthalmic gel formulation
US5163899A (en) 1987-03-20 1992-11-17 Drug Delivery Systems Inc. Transdermal drug delivery system
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
GB8804164D0 (en) 1988-02-23 1988-03-23 Tucker J M Bandage for administering physiologically active compound
US4882150A (en) 1988-06-03 1989-11-21 Kaufman Herbert E Drug delivery system
US5008110A (en) 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
US5088977A (en) 1988-12-21 1992-02-18 Drug Delivery Systems Inc. Electrical transdermal drug applicator with counteractor and method of drug delivery
DE69034007T2 (de) 1989-04-28 2003-05-08 Riker Laboratories Inc., Northridge Inhalationsvorrichtung für Trockenpulver
US5521222A (en) 1989-09-28 1996-05-28 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
ES2055280T3 (es) 1989-12-04 1994-08-16 Searle & Co Sistema monocapa para la administracion transdermica de farmacos.
US5364833A (en) 1990-05-09 1994-11-15 Basf Aktiengesellschaft Cyclohexenone oxime ethers, their preparation and their use as herbicides
US5077033A (en) 1990-08-07 1991-12-31 Mediventures Inc. Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide
DK0495421T3 (da) 1991-01-15 1996-12-09 Alcon Lab Inc Anvendelse af carragenaner i topiske ophthalmiske sammensætninger
US5404871A (en) 1991-03-05 1995-04-11 Aradigm Delivery of aerosol medications for inspiration
US6060069A (en) 1991-05-20 2000-05-09 Dura Pharmaceuticals, Inc. Pulmonary delivery of pharmaceuticals
US5492112A (en) 1991-05-20 1996-02-20 Dura Pharmaceuticals, Inc. Dry powder inhaler
US5327883A (en) 1991-05-20 1994-07-12 Dura Pharmaceuticals, Inc. Apparatus for aerosolizing powdered medicine and process and using
US5352456A (en) 1991-10-10 1994-10-04 Cygnus Therapeutic Systems Device for administering drug transdermally which provides an initial pulse of drug
IL104068A (en) 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
CA2123809A1 (en) 1991-12-18 1993-06-24 Debra L. Wilfong Multilayered barrier structures
US5320094A (en) 1992-01-10 1994-06-14 The Johns Hopkins University Method of administering insulin
EP0553769B1 (de) 1992-01-29 1996-01-03 FRANZ VÖLKL GmbH & CO. SKI UND TENNIS SPORTARTIKELFABRIK KG Ballspielschläger, insbesondere Tennisschläger
US5277195A (en) 1992-02-03 1994-01-11 Dura Pharmaceuticals, Inc. Portable spirometer
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
ATE174804T1 (de) 1992-10-19 1999-01-15 Dura Pharma Inc Trockenpulverinhalator
US6131567A (en) 1993-01-29 2000-10-17 Aradigm Corporation Method of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin
WO1994016756A1 (en) 1993-01-29 1994-08-04 Miris Medical Corporation Intrapulmonary delivery of hormones
US5743250A (en) 1993-01-29 1998-04-28 Aradigm Corporation Insulin delivery enhanced by coached breathing
US5364838A (en) 1993-01-29 1994-11-15 Miris Medical Corporation Method of administration of insulin
US5672581A (en) 1993-01-29 1997-09-30 Aradigm Corporation Method of administration of insulin
US5558085A (en) 1993-01-29 1996-09-24 Aradigm Corporation Intrapulmonary delivery of peptide drugs
US5661130A (en) 1993-06-24 1997-08-26 The Uab Research Foundation Absorption enhancers for drug administration
TW402506B (en) 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
US5506203C1 (en) 1993-06-24 2001-02-06 Astra Ab Systemic administration of a therapeutic preparation
BR9507023A (pt) 1994-03-07 1997-09-23 Inhale Therapeutic Syst Processos para aerossolização de uma dose de insulina para a liberação respiratória de insulina e para preparação de uma composição de insulina e composição de insulina
IL114193A (en) 1994-06-20 2000-02-29 Teva Pharma Ophthalmic pharmaceutical compositions based on sodium alginate
ES2094688B1 (es) 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
US5780014A (en) 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US5645051A (en) 1995-04-21 1997-07-08 Dura Pharmaceuticals, Inc. Unit dose dry powder inhaler
US5622166A (en) 1995-04-24 1997-04-22 Dura Pharmaceuticals, Inc. Dry powder inhaler delivery system
US5654007A (en) 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
US5700904A (en) 1995-06-07 1997-12-23 Eli Lilly And Company Preparation of an acylated protein powder
IT1283911B1 (it) 1996-02-05 1998-05-07 Farmigea Spa Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo
US5800807A (en) 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
ZA989744B (en) 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
US6261547B1 (en) 1998-04-07 2001-07-17 Alcon Manufacturing, Ltd. Gelling ophthalmic compositions containing xanthan gum
US6197934B1 (en) 1998-05-22 2001-03-06 Collagenesis, Inc. Compound delivery using rapidly dissolving collagen film
US6241969B1 (en) 1998-06-26 2001-06-05 Elan Corporation Plc Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
US20020006901A1 (en) 1999-02-05 2002-01-17 Aldo T. Iacono Use of aerosolized cyclosporine for prevention and treatment of pulmonary disease
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
WO2001051030A1 (en) 2000-01-10 2001-07-19 Dura Pharmaceuticals, Inc. Pharmaceutical formulation and method for pulmonary and oral delivery
US6897240B2 (en) 2002-05-08 2005-05-24 The Regents Of The University Of California Thio semicarbazone and semicarbazone inhibitors of cysteine proteases and methods of their use
WO2005087211A1 (en) 2004-03-05 2005-09-22 The Regents Of The University Of California Anti-parasitic compounds and methods of their use
US8173696B2 (en) * 2007-06-13 2012-05-08 Baylor University Inhibitors of cysteine proteases and methods of use thereof
JP5711142B2 (ja) 2008-12-12 2015-04-30 ザ ユニバーシティ オブ メルボルン 非対称性ビス(チオセミカルバゾン)の調製方法
JP6231548B2 (ja) * 2012-03-23 2017-11-15 マテオン セラピューティクス, インコーポレイテッド カテプシンの阻害のための組成物および方法

Also Published As

Publication number Publication date
EP2828241A4 (en) 2016-06-29
US20150031915A1 (en) 2015-01-29
AU2013235729A1 (en) 2014-10-09
EP2828241B1 (en) 2018-09-12
US20130296605A1 (en) 2013-11-07
US9873668B2 (en) 2018-01-23
WO2013142038A2 (en) 2013-09-26
US8877967B2 (en) 2014-11-04
US20160368869A1 (en) 2016-12-22
US9458103B2 (en) 2016-10-04
EP2828241A2 (en) 2015-01-28
WO2013142038A3 (en) 2015-06-18
JP6231548B2 (ja) 2017-11-15
JP2015521156A (ja) 2015-07-27
AU2013235729B2 (en) 2017-06-01
CA2865504A1 (en) 2013-09-26

Similar Documents

Publication Publication Date Title
NZ629898A (en) Compositions and methods for inhibition of cathepsins
ZA201701299B (en) Glycosidase inhibitors
SA520412335B1 (ar) مشتقات أوكسي فلورو ببريدين كمثبط كيناز
PH12018500061A1 (en) Oxysterols and methods of use thereof
CY1121357T1 (el) Νεος ανοσοτροποποιητης και αντιφλεγμονωδεις ενωσεις
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
MX2018010192A (es) Inhibidores de glucosidasa.
PH12015502031A1 (en) Tetrahydropyrrolothiazine compounds
PH12018500065B1 (en) Oxysterols and methods of use thereof
IN2015DN01156A (enExample)
EA201201648A1 (ru) Стимуляторы sgc
CR20150078A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
EA201290800A1 (ru) Гетероциклическое соединение
MX2016002794A (es) Compuestos antiproliferativos.
MX2018010191A (es) Inhibidores de glucosidasa.
UA111382C2 (uk) Інгібітори протеїнкінази
TN2020000125A1 (en) Amino-fluoropiperidine derivative as kinase inhibitor
MX2021014531A (es) Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos.
TN2015000245A1 (en) Heterocyclic compound
MX2017013880A (es) Derivados del acido tetrahidronaftiridinil propionico y usos de los mismos.
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
GEP20156315B (en) Oxazoline and isoxazoline derivatives as crac modulators
MX2010002042A (es) Derivados de 1,3-dihidroisoindol.
MX2017005422A (es) Inhibidores de histona desacetilasa y sus usos en terapia.
MX2015016332A (es) Inhibidores de alk biciclicos fusionados.

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 MAR 2018 BY COMPUTER PACKAGES INC

Effective date: 20170218

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 MAR 2019 BY CPA GLOBAL

Effective date: 20180303

LAPS Patent lapsed